256 Newsroom — Uganda's Digital News Infrastructure
Business

Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III - 247wallst.com

Published by 24/7 Wall St. By David Moadel · 1 September 2026 at 21:00
Share
Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III - 247wallst.com
Image · 24/7 Wall St.

What the report says

GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real value of mRNA technology sits right now.

Read the full report at 24/7 Wall St. →

Loading debate for this article…

Other publishers covering this story

No additional verified coverage is currently clustered with this report.

More stories by this journalist

Other publications from this journalist — open any story without leaving the article page.

No other published stories from this publisher yet.

Related reporting

Uganda’s informal economy seeks strength in numbersThe Observer 256 Newsroom Gen Saleh Calls for Review of Caged-Fishing and Coffee-Farming Projects - ChimpReportsChimpReports 256 Newsroom King Oyo’s legacy: How a boy monarch redefined Uganda’s cultural resilience - monitor.co.ugDaily Monitor Gen. Saleh Calls For Review Of Caged-Fishing And Coffee-Farming ProjectsWatchdog Uganda Rubanda Launches Shs40m Road Project to Boost Farm-to-Market AccessNile Post 256 Newsroom Nabacwa's purse strings and FTB's promise: Women's football learns to bank on itself - Daily MonitorDaily Monitor